No connection

Search Results

ABBV vs AXSM

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
AXSM
Axsome Therapeutics, Inc.
BEARISH
Price
$185.96
Market Cap
$9.37B
Sector
Healthcare
AI Confidence
68%

Valuation

P/E Ratio
ABBV
163.63
AXSM
--
Forward P/E
ABBV
15.42
AXSM
423.03
P/B Ratio
ABBV
-146.66
AXSM
126.85
P/S Ratio
ABBV
6.5
AXSM
16.7
EV/EBITDA
ABBV
15.27
AXSM
-49.31

Profitability

Gross Margin
ABBV
71.46%
AXSM
91.86%
Operating Margin
ABBV
35.5%
AXSM
-19.25%
Profit Margin
ABBV
4.0%
AXSM
-40.89%
ROE
ABBV
137.96%
AXSM
-275.5%
ROA
ABBV
9.59%
AXSM
-19.79%

Growth

Revenue Growth
ABBV
9.1%
AXSM
63.2%
Earnings Growth
ABBV
-88.7%
AXSM
--

Financial Health

Debt/Equity
ABBV
--
AXSM
2.96
Current Ratio
ABBV
0.72
AXSM
1.57
Quick Ratio
ABBV
0.47
AXSM
1.45

Dividends

Dividend Yield
ABBV
3.05%
AXSM
--
Payout Ratio
ABBV
490.15%
AXSM
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
AXSM BEARISH

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant operational and profitability concerns. Despite strong revenue growth of 63.2% and a bullish analyst recommendation, the company is deeply unprofitable with a -40.89% profit margin, negative ROE of -275.50%, and a high debt/equity ratio of 2.96. Valuation metrics are stretched, with a forward P/E of 423x and a price-to-book of 126.85, while insider selling of $85.54M in the last six months signals strong bearish sentiment from management. Although the stock has delivered impressive price performance over the past year (+79%), these gains appear disconnected from fundamentals, increasing vulnerability to downside correction.

Strengths
Exceptional year-over-year revenue growth of 63.20%, significantly above sector average of 39.78%
High gross margin of 91.86%, indicating strong pricing power and low cost of goods sold
Analyst consensus is strong_buy with a target price of $210.19, implying 13% upside
Risks
Piotroski F-Score of 3/9 indicates weak financial health and poor profitability trends
Extremely high forward P/E of 423x with no Graham Number, suggesting severe overvaluation relative to earnings
Negative ROE of -275.50% and negative operating margins signal deep profitability issues

Compare Another Pair

ABBV vs AXSM: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Axsome Therapeutics, Inc. (AXSM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile